Facts of Tafinlar (dabrafenib)
Product: TAFINLAR (dabrafenib) capsules, for oral use.
Initial U.S. Approval: 2013
Strength: Capsules: 50 mg, 75 mg
indication: metastatic melanoma with BRAF V600E mutation. non-small cell lung cancer (NSCLC).
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Tafinlar (dabrafenib) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Tafinlar (dabrafenib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
What Tafinlar is?
- TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
- TAFINLAR in combination with trametinib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.
What Dabrafenib is?
Dabrafenib, sold under the brand name Tafinlar, is a medication for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF (V600)-mutated metastatic melanoma.
The US Food and Drug Administration initially approved dabrafenib as a single agent treatment for patients with BRAF V600E mutation-positive advanced melanoma on May 29, 2013.Dabrafenib was approved for use in the European Union in August 2013. In April 2017, the European Union approved the combination of dabrafenib with trametinib for BRAF V600-positive advanced or metastatic non small-cell lung cancer (NSCLC).